Adding cetuximab to concurrent chemoradiotherapy did not improve overall survival in patients with adenocarcinoma or squamous cell carcinoma of the esophagus according to findings of RTOG 0436, a randomized phase III trial presented by David Ilson, MD, of Memorial Sloan Kettering Cancer Center, at the 16th World Congress of Gastrointestinal Cancer on June 26, 2014.
http://www.onclive.com/conference-coverage/world-GI-2014/Adding-Cetuximab-to-Chemoradiation-in-Non-operable-Esophageal-Cancer-Does-Not-Improve-Survival
Adding Cetuximab to Chemoradiation in Non-operable Esophageal Cancer Does Not Improve Survival